Skip to main content
Terug
RLMD logo

Relmada Therapeutics, Inc.

Datakwaliteit: 100%
RLMD
NASDAQ Healthcare Biotechnology
CEO: Sergio Traversa Employees: 17 IPO: Jun 20, 2014
Prijs
€ 6,96
Verandering
▲ € 0,58
9,09%
Marktkapitalisatie
510,40M
Dagbereik
€ 6,38 € 6,96
52-Weeksbereik
€ 0,24 € 7,51
Volume
2.185.032
50D / 200D Gem.
€ 4,80
€ 2,83
Vorige Slotkoers
€ 6,38

Quick Summary

Belangrijkste Punten

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -45,79M
PEG of 0,07 suggests growth is underpriced

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-94,05%
Onder sectorgemiddelde (3,68%)
ROIC-51,24%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,00
Onder sectorgemiddelde (0,24)
Current Ratio14,62
Interest Coverage0,00

Waardering

P/E Ratio
-8,89
Onder sectorgemiddelde (0,23)
Forward P/EN/A
P/B Ratio5,90
EV/EBITDAN/A
Dividend Yield0,00%

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (635 peers)

Metriek Aandeel Sector Mediaan
P/E -8,9 0,2
P/B 5,9 2,9
ROE % -94,1 3,7
Net Margin % 3,9
Rev Growth 5Y % 9,6
D/E 0,0 0,2

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -57,39M
ROE -94,05% ROA -61,05%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -45,79M
ROIC -51,24% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 14,62
Interest Coverage 0,00
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -8,89 Forward P/E N/A
P/B Ratio 5,90 P/S Ratio N/A
PEG Ratio 0,07 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -8,97%
Market Cap 510,40M Enterprise Value 506,91M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -57,39M -79,98M -98,79M -157,04M -125,75M
EPS (Diluted) -1,45 -2,65 -3,28 -5,30 -7,16
Gross Profit 0,0 0,0 0,0 0,0 0,0
Operating Income -59,10M -83,89M -103,70M -161,25M -125,70M
EBITDA -59,10M -83,89M 4,91M -161,25M -125,70M
R&D Expenses 744.560,0 46,18M 54,81M 113,32M 90,62M
SG&A Expenses 311.904,0 37,72M 48,90M 47,93M 35,08M
D&A 0,0 0,0 103,70M 2.000,0 1.258,0
Interest Expense 0,0 0,0 0,0 0,0 0,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 94,00M 45,82M 97,55M 152,91M 223,33M
Total Liabilities 7,49M 10,30M 12,19M 12,47M 15,06M
Shareholders' Equity 86,51M 35,52M 85,36M 140,44M 208,26M
Total Debt 0,0 0,0 0,0 0,0 0,0
Cash & Equivalents 3,50M 3,86M 4,09M 5,40M 44,44M
Current Assets 93,98M 45,80M 97,51M 152,87M 223,30M
Current Liabilities 6,43M 10,29M 12,19M 12,47M 15,06M